FDA Regulatory Education For Industry (REdI) Annual Conference 2023 Is June 5-9, 2023.
Will they be discussing the fact that may products are experimental and used without informed consent? When discussing regulatory rules do they discuss ETHICS? Attend and find out!
Heads up The FDA is allegedly actually educating the Industry and consulting professionals working with advanced therapies, cell- or tissue-based products, and devices used with biological products…
Read below & sign up to attend and ask a question or more if you wish.
Regulatory Education for Industry (REdI) Annual Conference 2023
JUNE 5 - 9, 2023
On This Page
Date:
June 5 - 9, 2023
Time:
8:40 AM - 4:30 PM ET
Virtual - Attend online
Attend
Visit CDER Small Business and Industry Assistance Page
Drugs, Devices, and Biologics
Learn directly from the FDA’s regulatory experts in medical product centers: drugs, devices, and biologics. This course is designed to provide participants with a strong, basic foundation in the FDA’s regulatory requirements, and also create awareness of current activities.
KEYNOTE SPEAKER
Robert M. Califf M.D., MACC
Commissioner of Food and Drugs
Patrizia Cavazzoni M.D.
Director
Center for Drug Evaluation and Research (CDER)
Jeff Shuren M.D., J.D.
Director
Center for Devices and Radiological Health (CDRH)
Peter Marks M.D., PhD.
Director
Center for Biologics Evaluation and Research (CBER)NO COST Conference
PLENARY
Federal law authorizes the FDA to collect user fees which help the FDA fulfill its mission of promoting and protecting the public health. Most major user fee programs run in five-year cycles, and the past year saw the launch of the current cycle for CDER, CBER, and CDRH. This session will take a closer look at the impact of user fee legislation, how the FDA advances programs through user fees support, and highlights of some of the exciting new efforts planned during this user fee cycle.
DRUGS TRACK
The drugs track will continue its focus on PDUFA VII commitments. Subject matter experts will provide cutting edge insights and perspectives on how several of these goals and initiatives are being implemented. Agenda topics will provide practical information and advances in bioinformatics (eCTD v4.0; ESG; data standards); digital health technologies, real-world evidence (RWE) & pilot programs.
Topics Include
New Meeting Types, including What's New Under PDUFA, BsUFA, and OMUFA
PDUFA VII Chemistry, Manufacturing, and Controls (CMC) Assessment Updates
Use-Related Risk Analysis (URRA) and Human Factor (HF) Protocol Reviews: What to Submit for an Efficient Review
Intended Audience
Regulatory affairs and other professionals working on the development and preparation of new drug submissions, drug safety and IT
Sponsors, applicant holders, manufacturers, clinical researchers and regulatory affairs professionals wishing to gain insight on INDs, NDAs and BLAs
Industry professionals at all levels of expertise
DEVICES TRACK
The devices track will provide an overview and highlights of how to get a new medical device to market. It will also discuss some best practices for ensuring that medical devices maintain their quality and continue to be safe and effective once on the market; and offer technical topic updates on biocompatibility, artificial intelligence, and radiological health.
Topics Include
Artificial Intelligence and Machine Learning; FDA Medical Device Inspections & Form FDA 483
Premarket Notification [510(k)] Program; Quality System Principles
Tips and Best Practices for High Quality Regulatory Submissions
Intended Audience
A new regulatory affairs specialist wanting to learn some basics and best practices for getting started with FDA’s regulation of medical devices.
A researcher of a medical device seeking to learn about the valid scientific evidence requirements needed to support new medical device regulatory submissions.
An establishment seeking to understand their regulatory responsibilities for handling complaints about their medical devices.
BIOLOGICS TRACK
The biologics track will focus on the developmental and regulatory topics relevant to advanced therapies, including cellular and gene therapies, tissue-engineered and other biological products. The speakers will present updates on programmatic enhancements mandated by PDUFA-VII, including new regulatory programs, stakeholder communications and much more.
Topics Include
IND readiness: contents of preclinical and clinical parts; Expanded Access INDs
Product development challenges and Chemistry, Manufacturing, and Controls (CMC) Developmental Readiness Pilot program
Estimand and Complex Innovative Design (CID) Program in application to CBER biologics
Intended Audience
Biotechnology product manufacturers, academic sponsors, and other stakeholders working on the development of advanced therapies
Regulatory affairs and other professionals working with submissions of INDs and BLAs to the Office of Therapeutic Products (OTP) in the Center for Biologics Evaluation and Research
Industry and consulting professionals working with advanced therapies, cell- or tissue-based products, and devices used with biological products
FDA RESOURCES
Plenary
Drugs
Devices
Biologics
CONTINUING EDUCATION
This five-day event has been approved for 32.25 contact hours of continuing education for physicians, pharmacists, and nurses. Please see detailed announcement for more information. After the course concludes, that day's attendees will receive an email with instructions and a code to claim their credit. Only participants who attend the live broadcast via Adobe Connect will receive the claim code.
Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations. Certificates are only available during the two weeks post-event.
This event has been pre-approved by:
RAPS as eligible for a maximum of 12 credits for a two-day event (appropriate to real-time attendance) towards a participant’s RAC recertification upon full completion.
SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.
SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant’s RQAP re-registration.
approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.
TECHNICAL INFORMATION
To optimize your webinar experience, use Chrome when viewing Adobe Connect in a browser.
Please contact info@sbiaevents.com for all technical questions.
If you encounter any technical issues before or during the event, please visit the Technical Issues SupportExternal Link Disclaimer.
Test your PC for use with Adobe ConnectExternal Link Disclaimer prior to the day of the event. Adobe, the Adobe logo, Acrobat and Acrobat Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.
IOJ has been trying to educate FDA about their own regulatory guidelines for quite some time. IOJ is suing the FDA for violations of their guidelines so we are not sure how they are in the position to educate anyone or the pharmaceutical industry which funds them and has captured the FDA.
Donate to help IOJ sue the FDA asap for violating Nuremberg Code and laws against serious undue experimentation. We can prove it! Help us sue FDA!
Below IOJ’s previous history with the FDA so you can catch up to speed
